分別以卡巴得單一劑量以每公斤體重3.5 mg口服方式及飼料添加卡巴得55 ppm投予豬隻 ( 連續兩週 ) 後,以液相層析連接串聯式質譜法分析豬隻血漿、肌肉、肝臟及腎臟中原型藥物及代謝物quinoxaline-2-carboxylic acid ( QCA ) 分佈及殘留情形。本分析方法其卡巴得及QCA檢測極限分別為0.002及0.180 ng/g,定量極限分別為0.005及0.606 ng/g。卡巴得單一劑量口服後其血中藥物濃度在給藥後2.6小時達到高峰;QCA分別在停藥後5週之肝臟 ( 1.98 ng/g ) 及停藥後6週之腎臟 ( 0.9 ng/g ) 中仍可測得。卡巴得平均穩定狀態分佈體積 ( 4427.39 ± 2070.30 mL/kg ) 及平均曲線下面積 ( 2327.58 ± 580.93 hr ng/mL ) 顯示其自豬隻血中迅速分佈至身體組織中。卡巴得代謝物排除緩慢,故豬隻投藥後供消費者食用前需經較長時間之停藥期。
The tissue distribution and residue depletion of carbadox and its metabolite ( quinoxaline-2-carboxylic acid, QCA ) were investigated in swine after a single oral dose of 3.5 mg/kg body weight of carbadox and multiple dose ( 2 weeks ) in-feed ( 55 ppm ) administration. Plasma, muscle, liver and kidney were sampled pre and post-treatment and subsequently analyzed for carbadox and QCA concentrations using liquid chromatography with tandem mass spectrometry ( LC-MS-MS ). The limits of detection of carbadox and QCA were 0.002 and 0.180 ng/g, the limits of quantitation were 0.005 and 0.606 ng/g for standard solution. Carbadox concentration in plasma was peaked on 2.6 hr after a single oral dose administration, while QCA concentration was still detected in liver ( 1.98 ng/g ) on the fifth week and kidney ( 0.9 ng/g ) on the sixth week after withdrawal. The apparent volume of distribution of carbadox at steady-state ( 4427.39 ± 2070.30 mL/kg ) and areas under the concentration curves ( 2327.58 ± 580.93 hr ng/mL ) indicates that the drug is adequately distributed throughout the body from the blood of pigs. The slow elimination of the carbadox metabolites suggests a need for long withdrawal periods prior to use of dosed swine for human consumption.